105 related articles for article (PubMed ID: 12237470)
1. Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering.
Lee MH; Maskos K; Knäuper V; Dodds P; Murphy G
Protein Sci; 2002 Oct; 11(10):2493-503. PubMed ID: 12237470
[TBL] [Abstract][Full Text] [Related]
2. Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme.
Lee MH; Rapti M; Murphy G
J Biol Chem; 2004 Oct; 279(43):45121-9. PubMed ID: 15308656
[TBL] [Abstract][Full Text] [Related]
3. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme.
Lee MH; Rapti M; Murphy G
J Biol Chem; 2005 Apr; 280(16):15967-75. PubMed ID: 15713681
[TBL] [Abstract][Full Text] [Related]
4. Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme.
Lee MH; Dodds P; Verma V; Maskos K; Knäuper V; Murphy G
Biochem J; 2003 Apr; 371(Pt 2):369-76. PubMed ID: 12556225
[TBL] [Abstract][Full Text] [Related]
5. Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme.
Lee MH; Verma V; Maskos K; Nath D; Knäuper V; Dodds P; Amour A; Murphy G
Biochem J; 2002 May; 364(Pt 1):227-34. PubMed ID: 11988096
[TBL] [Abstract][Full Text] [Related]
6. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex.
Wisniewska M; Goettig P; Maskos K; Belouski E; Winters D; Hecht R; Black R; Bode W
J Mol Biol; 2008 Sep; 381(5):1307-19. PubMed ID: 18638486
[TBL] [Abstract][Full Text] [Related]
7. Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase.
Lee MH; Knäuper V; Becherer JD; Murphy G
Biochem Biophys Res Commun; 2001 Jan; 280(3):945-50. PubMed ID: 11162616
[TBL] [Abstract][Full Text] [Related]
8. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition.
Lee MH; Rapti M; Knaüper V; Murphy G
J Biol Chem; 2004 Apr; 279(17):17562-9. PubMed ID: 14734567
[TBL] [Abstract][Full Text] [Related]
9. The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3.
Lee MH; Verma V; Maskos K; Becherer JD; Knäuper V; Dodds P; Amour A; Murphy G
FEBS Lett; 2002 Jun; 520(1-3):102-6. PubMed ID: 12044879
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 regulates TNF-alpha-converting enzyme (TACE/ADAM-17) involving a TIMP-3 dependent and independent mechanism.
Brennan FM; Green P; Amjadi P; Robertshaw HJ; Alvarez-Iglesias M; Takata M
Eur J Immunol; 2008 Apr; 38(4):1106-17. PubMed ID: 18383040
[TBL] [Abstract][Full Text] [Related]
11. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
Wei S; Xie Z; Filenova E; Brew K
Biochemistry; 2003 Oct; 42(42):12200-7. PubMed ID: 14567681
[TBL] [Abstract][Full Text] [Related]
12. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.
Wei S; Kashiwagi M; Kota S; Xie Z; Nagase H; Brew K
J Biol Chem; 2005 Sep; 280(38):32877-82. PubMed ID: 16079149
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.
Amour A; Slocombe PM; Webster A; Butler M; Knight CG; Smith BJ; Stephens PE; Shelley C; Hutton M; Knäuper V; Docherty AJ; Murphy G
FEBS Lett; 1998 Sep; 435(1):39-44. PubMed ID: 9755855
[TBL] [Abstract][Full Text] [Related]
14. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.
Kassiri Z; Oudit GY; Sanchez O; Dawood F; Mohammed FF; Nuttall RK; Edwards DR; Liu PP; Backx PH; Khokha R
Circ Res; 2005 Aug; 97(4):380-90. PubMed ID: 16037568
[TBL] [Abstract][Full Text] [Related]
15. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.
Karan D; Lin FC; Bryan M; Ringel J; Moniaux N; Lin MF; Batra SK
Int J Oncol; 2003 Nov; 23(5):1365-71. PubMed ID: 14532978
[TBL] [Abstract][Full Text] [Related]
16. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats.
Tang ZY; Loss G; Carmody I; Cohen AJ
Transplantation; 2006 Dec; 82(11):1518-23. PubMed ID: 17164725
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the cDNA and gene for mouse tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and its location to mouse chromosome 12 and human chromosome 2p25.
Cerretti DP; Poindexter K; Castner BJ; Means G; Copeland NG; Gilbert DJ; Jenkins NA; Black RA; Nelson N
Cytokine; 1999 Aug; 11(8):541-51. PubMed ID: 10433800
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).
Kveiborg M; Jacobsen J; Lee MH; Nagase H; Wewer UM; Murphy G
Biochem J; 2010 Aug; 430(1):79-86. PubMed ID: 20533908
[TBL] [Abstract][Full Text] [Related]
19. Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.
Hamze AB; Wei S; Bahudhanapati H; Kota S; Acharya KR; Brew K
Protein Sci; 2007 Sep; 16(9):1905-13. PubMed ID: 17660250
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
